Biologics / Biotechnology

UK financial markets
#BioIndustry Association #Biologics / Biotechnology #Clarivate #Investment #Market reporting #Mergers and acquisitions #Private investment #Seed funding #UK

UK biotech investment drops after bumper years

Investment in UK biotech has fallen from £4.5 billion in 2021 to just £1.8 billion in 2022, mirroring the global economic downturn impacting all sectors.  However, venture capital investment in the sector was the third-best year recorded for the UK, with £1.2 billion raised, new analysis from the UK BioIndustry… Read More

#Business & Investment #News

Neurons in Parkinson's disease
#Biologics / Biotechnology #Collaboration #Drug discovery #Library screening #Neurodegenerative disorders #Partnership #Sironax #X-Chem

Research partners will target neurodegenerative disease

X-Chem and Sironax have agreed a research partnership, in which X-Chem will use its DEL platform to support Sironax’s drug discovery pipeline.   Through the collaboration, X-Chem will screen its DNA-encoded libraries (DEL) against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute these hits into… Read More

#Business & Investment #News

US Food and Drug Administration
#Biologics / Biotechnology #Celltrion #Crohn's disease #FDA #Inflammatory Bowel Disease #Phase III trial #United States

First subcutaneous formulation of infliximab submitted to FDA

Celltrion USA has submitted a Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act for CT-P13 SC for the treatment of inflammatory bowel disease (IBD).  The submission is based on results from the Phase III pivotal data that evaluated the efficacy and safety of… Read More

#News #Regulatory

#Biologics / Biotechnology #Cell and gene therapy #Covid-19 #Drug discovery #mRNA-based vaccines #Plant-based #Synthetic biology #Ukraine

DDW’s best of 2022: What were your top reads?

2022 was a complicated year. Global challenges like the Ukraine war and the continued impact of Covid-19 have been felt across the world. And yet it was also a year of incredible innovation in drug discovery, with the potential of new biotechnology beginning to be revealed. Our top 10 most… Read More

#Editor's Choice #Exclusive Content #News

Neuronal inclusions in Huntington’s disease
#Alchemab #Antibodies #Biologics / Biotechnology #Funding #Medicines Discovery Catapult #Neurodegenerative disorders #Neuroscience

£1.7M awarded to accelerate therapy for Huntington’s disease

Biotechnology company Alchemab Therapeutics has been awarded a grant of £1.7 million (US$2 million) from Innovate UK’s Biomedical Catalyst 2022 funding competition, to accelerate development of a first-in-class disease modifying therapy for Huntington’s disease.   Working in collaboration with Medicines Discovery Catapult (MDC), Alchemab is carrying out preclinical… Read More

#News

Protein
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #BioInnovation Institute #Biologics / Biotechnology #Investment #Proteins #Start-ups

Therapeutic protein project joins Bio Studio programme

A project creating a new class of therapeutic proteins to modulate cell signalling has been accepted into the BioInnovation Institute (BII) Bio Studio programme. The project is based on recent breakthroughs in artificial intelligence (AI) and protein design, and uses methods pioneered by David Baker’s laboratory at the University of… Read More

#News #Start-up Zone

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biopharmaceuticals #Cell and gene therapy #Diversity #Market reporting #Mergers and acquisitions #Personalised medicine #Pharmaceutical industry #Precision medicine

Drug discovery in 2023: Five key predictions

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023.  1. There will be greater emphasis on diversity in clinical trials A… Read More

#Exclusive Content #Trends & Analysis

#Biologics / Biotechnology #Cancer research #Financing #Investment #Oncology #RNA

Biotech company raises $30M to target RNA modifying enzymes

Clinical biotechnology company Storm Therapeutics has successfully completed a USD $30 million Series B financing round.  The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases.  The financing was co-led by existing investors M Ventures,… Read More

#Business & Investment #News

#Biologics / Biotechnology #CAR-T #China #CRISPR #Drug discovery #Gene editing #Genetics / genomics #HIV #HPV #Oncology #Pharmacology #T cell activation #The Dose

The Dose: DDW’s drug discovery highlights

DDW highlights the most interesting global news and comments within the drug discovery and development sector this month.   Everyone enjoys a good news story and the drug discovery and development sector is no exception. Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening… Read More

#Exclusive Content

Enzymes
#Biologics / Biotechnology #Collaboration #Enzymes #High throughput screening #Partnership #Synthetic biology

Partnership hopes to accelerate protein discovery

GenScript Biotech, a provider of life-science research tools and services, is partnering with Allozymes, a Singapore-based biotech startup, with aims to accelerate the enzyme discovery and development process.  In the partnership, GenScript will provide the mutant libraries construction and expression, while Allozymes will provide ultra-high-throughput screening for… Read More

#News

#Biologics / Biotechnology #Cancer research #Collaboration #Europe #Gene therapy #Lung cancer

International consortium launches €12.8 million lung cancer project

Irish biotech company OmniSpirant and French biotech EVerZom have joined other partners to launch INSPIRE, a €12.8 million lung cancer project funded by Horizon Europe.   The project gathers European partners spanning across biotechnology, medical devices, cancer research, academia and patient advocacy. Over the next three years, the consortium… Read More

#Cancer Research #News

#Biologics / Biotechnology #New appointment #Pharmaceutical industry #Recruitment

Who are drug discovery’s latest movers and shakers?

There have been a number of high-level career moves within the industry in the last couple of weeks. In this update, we provide a round-up of the latest senior appointments and promotions. Nick Maishman, ViroCell Biologics Nick Maishman has joined contract development and manufacturing organisation ViroCell as Chief Operating Officer. Read More

#Business & Investment #News

Builders checking plans
#Biologics / Biotechnology #Biotech hubs #Cell and gene therapy #Drug discovery #Expansion #Investment #Laboratory #Manufacturing

Space to innovate: where are biotech’s top expansions?

Expansions to laboratory space throughout the drug discovery industry can only be a good thing – new centres of innovation will bring more space to grow, more advanced technologies, improved sustainability and new employment opportunities.  While there have been a significant number of new facilities built in the US,… Read More

#Editor's Choice #News

Scientist filling test tubes in biotechnologymlab
#Biologics / Biotechnology #EIT Health #European Commission #Investment #Regulatory #Start-ups

Partnership supports biotech start-ups on journey to market

ProductLife Group has been chosen as the exclusive Privileged Partner for Regulatory & Compliance services by EIT Health’s Venture Centre of Excellence (VCoE). The partnership means EIT Health will… Read More

#News

UK on global map
#BioIndustry Association #Biologics / Biotechnology #Equity finance #Finance #Fundraising #Investment #Life sciences #Market reporting #Private investment #Seed funding #UK

UK remains strongest biotech hub in Europe despite general decline

After a disappointing start to the year, the last few months have seen a boost to fundraising for UK biotech companies. DDW’s Diana Spencer unpacks the Q3 figures and annual predictions from the BioIndustry Association1.  While 2021 was the highest year on record for investments into UK biotech and life… Read More

#Business & Investment #Exclusive Content #Market Reports

Basel map
#Biologics / Biotechnology #Cancer immunotherapy #Immuno-oncology #Market reporting #Oncology #Start-ups

Basel: a centre for ground-breaking oncology 

Listen to this article on the DDW podcast: Dr Stephan Emmerth and Paul Eschmann, Basel Area Business & Innovation, explain the benefits of being based in Basel – the talent pool, global players, academic institutions and investors, for example.  Companies specialising in oncology R&D and therapeutics continue to spring up all… Read More

#Exclusive Content #Market Reports